RECENT ADVANCEMENT IN INFERTILITY MANAGEMENT AND ADOPTION PROCESS.ppt
Ghana NDP 2014 REVIEW PROCESS.ppt(NMP) is the policy document providing guidance to the...
Transcript of Ghana NDP 2014 REVIEW PROCESS.ppt(NMP) is the policy document providing guidance to the...
WHO ENGLISH TBS, GENEVA, 3-8 NOVEMBER 2014
Ghana National Medicine
Policy Review 2014
The Process
4th November 2014
George Hedidor
B.Pharm, MPH
Prin. Pharmacist. Ministry of Health, Ghana
WHO ENGLISH TBS, GENEVA, 3-8 NOVEMBER 2014
Outline
�Introduction
�Review of the 2004 NMP
�Aims of the NMP
�Review Process
• Assessment of 2004 Document
• Stakeholder engagements
• Components of NMP
• Matters Arising from Stakeholder engagements
�Current status
�Acknowledgement
WHO ENGLISH TBS, GENEVA, 3-8 NOVEMBER 2014
Introduction
• The NDP to be renamed National Medicines Policy
(NMP) is the policy document providing guidance to
the pharmaceutical sector in Ghana
– 1st edition 1999
– 2nd edition 2004
– 3rd edition 2014 (have been under review since October
2013)
• It represents decisions based on the best current
evidence
• the consensus opinion of all stakeholders
• the general direction of governance on
pharmaceuticals and other related health
technologies
WHO ENGLISH TBS, GENEVA, 3-8 NOVEMBER 2014
Revision of 2004 NMP
� Revision has been necessitated by the need
to:
• strengthen pharmaceutical systems as a key
component of health systems to meet the ever-
changing health needs of the population
• sustain the gains made in ensuring financial
access to medicines for the poor and vulnerable
• develop local pharmaceutical industry,
• strengthen the regulation of pharmaceuticals in
Ghana
WHO ENGLISH TBS, GENEVA, 3-8 NOVEMBER 2014
Aim of the new NMP
�The new medicines policy aims to actualize the
commitment of the Government of Ghana towards
the goal of ensuring universal access to affordable
essential medicines of assured quality for all
persons living in Ghana, as well as their responsible
use by health professionals and consumers.
�To provide direction and guidance for all
stakeholders in the pharmaceutical sector towards
one common goal.
WHO ENGLISH TBS, GENEVA, 3-8 NOVEMBER 2014
The Review Process
� The NMP review process is deemed as equally important
as the output of the process (the policy itself)
Based on developments at the national and global levels
and reasons discussed above
•Independent assessment of the pharmaceutical sector in
2013 based on the 2004 NMP by WHO consultant, and
through several stakeholder consultations
�The basic aim of the assessment was to determine the level
of implementation of the 2004 policy
�Propose policy directions for 2014 - 2020
WHO ENGLISH TBS, GENEVA, 3-8 NOVEMBER 2014
Assessment of Medicines Policy
Cre
dit
: W
HO
Ass
ess
me
nt
of
the
20
04
Po
licy
in
20
13
7
GREEN (ON TRACK): Objectives achieved and/or policy component is on track
(middle) ORANGE (AT RISK): The objective is partially achieved and/or mechanisms are partly in
place, but more effort is needed to achieve the policy objective;
(top) RED (STAND-STILL): The activity has not started
WHO ENGLISH TBS, GENEVA, 3-8 NOVEMBER 2014
Process continues
• Dissemination of results of assessment to key
stakeholders
• The Minister of Health inaugurated a Technical
Working Group (TWG) to revised the policy
• Consider the assessment report and policy
recommendations
• Revise the 2004 NMP
• Draft a new NMP
WHO ENGLISH TBS, GENEVA, 3-8 NOVEMBER 2014
NMP Technical Working Group (TWG)Organization
School of Public Health, University of Ghana
Community Practice Pharmacist Association/Pharmaceutical Society of Ghana
Ghana National Drugs Programme, Ministry of Health
Pharmacy Council
Policy Planning Monitoring and Evaluation, Ministry of Health
WHO Country Office for Ghana
Society of Private Medical and Dental Practitioners
National Drug Information Resource Centre
Attorney General’s Office, Ministry of Justice
Medicines Transparency Alliance
Pharmaceutical Manufacturers Association of Ghana
Ghana Medical Association
UNIDO desk/Ministry of Trade and Industry
Ministry of Health
Food and Drug Authority
Traditional Medicines Directorate, Ministry of Health
National Health Insurance Authority
Procurement and Supply Directorate, Ministry of Health
WHO ENGLISH TBS, GENEVA, 3-8 NOVEMBER 2014
-------
• TWG worked in sub-committees based on different themes in
the document with co-opted members where appropriate
(e.g. NHIA, FDA, etc.)
• Developed a template for report for each sub group
• Retreat for TWG members to collate all responses and
consider the proposed policy statement
• The TWG has worked systematically based on the best
evidence to develop a revised 2014 DRAFT NMP.
WHO ENGLISH TBS, GENEVA, 3-8 NOVEMBER 2014
1. Broad Policy Area: [eg. Selection, procurement etc.] Comments
Response
1. Policy statement:
[The policy statement as it should appear in the policy document]
Comments
1. Implications of this policy statement, Financial/Economic/etc.
[NB: e.g. If you indicate that a policy has Economic implications, you must describe what that
implication is]
Comments
Response
1. Actions:
[Describe the Activities to be carried out in order to achieve the policy statement above]
Comments
Response
1. Justification(s):
[Indicate the justification for the activities indicated above. Also indicate whether it’s a short,
medium or long term activity]
Comments
Response
1. Indicators:
[List/indicate measurable Monitoring Indicator(s) for this policy statement]
Comments
Response
1. Please include possible data sources for the indicator above Comments
Response
1. Communication plan Comments
Response
9. Any other information, relating to this policy statement Comments
NB: The deadline for the submission of this work is 16th April 2014.
Working template for the Formulation of Policy Statements for the National Drug Policy Review 2013/2014GUIDEPlease note that sub-groups are to fill one form/template per policy statement to be included in the revised policy. The spaces provided could be extended to accommodate more information. Any other information not captured in this template can be provided under item 9. The section for comments is to capture any further details that give clarity on the specific item being described.
WHO ENGLISH TBS, GENEVA, 3-8 NOVEMBER 2014
Stakeholder engagement workshop
�Stakeholder engagement
• To ensure that all relevant stakeholders are involved in
charting the course of the management of
pharmaceuticals in the years ahead
�Advocacy and Information sharing
• To ensure that all relevant stakeholders are ‘on board’
� Consensus building
• To build consensus on some outstanding aspects of the
policy
�Stakeholder consultation
• To harness the views of stakeholders on aspects of the
revised policy
WHO ENGLISH TBS, GENEVA, 3-8 NOVEMBER 2014
Key components of the NMP
• Old components
– Selection of essential medicines and health technologies
– Financing
– Procurement medicines and other health technologies
– Quality assurance
– Local Manufacture
– Disposal of medicines
– Rational medicine use
– Global trade in pharmaceuticals and health technologies
– Emerging Diseases and Pharmaceuticals
– Human Resource Development for Drug Management
– Traditional Medicinal Products
– Research and development
– National Medicine Policy implementation
WHO ENGLISH TBS, GENEVA, 3-8 NOVEMBER 2014
Key components of the NMP• New components
• Health Technology Assessments
• Transparency and Accountability
• Governance (Good)
• Pricing
• Disposal of Medicines
• Suggested sections/statements on:
• AMR policy, Bioequivalence center
• New additions to strengthen policy implementation
• A costed Implementation Plan with defined roles, targets, SMART
objectives and indicators
• The implementation plan would also have:
• An advocacy and communications strategy
• A monitoring and evaluation framework
WHO ENGLISH TBS, GENEVA, 3-8 NOVEMBER 2014
Critical issues during stakeholder
consultations
� Policy on procurement
• Important policy interventions in procurement that ensures
efficiency and value for money. This has implications on
sustainability of reimbursements under NHIA
�Policy on pricing
• The expansion of the scope of the current section of draft policy on
pricing into a dedicated section as a pricing policy for Ghana
�Policy on Rational Use of Medicines
• policy to promote rational use of medicines in the community
• Issues around dispensing doctors and prescribing pharmacists
(separation of services)
�Strengthening of FDA, products, manufacturing,
wholesalers
WHO ENGLISH TBS, GENEVA, 3-8 NOVEMBER 2014
Critical issues during stakeholder
consultations
�Private sector involvement
• Strengthening private sector role in all relevant aspects of
the policy
�Implementation
• Engagement of implementing stakeholders to formulate
detailed activities, budgets and specific timelines; for
Policy Implementation Plan
�Prioritizing areas in the revised policy for
immediate action
• In the context of resource constrains, which aspects of the
revised policy must be addressed immediately as a priority
WHO ENGLISH TBS, GENEVA, 3-8 NOVEMBER 2014
Current status of the new NMP
�Inputs from stakeholders have been considered
by TWG to finalize the policy
�An implementation, advocacy and communication
plan, as well as an M and E framework has also been
drafted
�Process to engage:
• The Minister of Health, and other relevant Ministers,
National Development Planning Commission as well as
the Parliamentary Select Committee on Health for
Cabinet endorsement and implementation
WHO ENGLISH TBS, GENEVA, 3-8 NOVEMBER 2014
Acknowledgement
� Appreciation to the following:
• Director of Pharmaceutical Services (Martha Gyansa-
Lutterodt) for providing leadership
• Ghana National Drugs Programme
• Ministry of Health, Ghana
• Medicines Transparency Alliance (MeTA) Ghana
• WHO Country Office
• EU/ACP/WHO Renewed Partnership for strengthening
pharmaceutical systems
• TBS participants
WHO ENGLISH TBS, GENEVA, 3-8 NOVEMBER 2014
Stakeholder forum pictures
WHO ENGLISH TBS, GENEVA, 3-8 NOVEMBER 2014
Thank You
Merci